Looking at just lately accepted drugs and the pipelines of main pharmaceutical companies, there isn’t a lack of therapies that might probably be vital income drivers.

Analytics firm Clarivate, in its annual Drugs to Watch report, recognized 15 drugs which have the potential to develop into blockbusters. The drugs are projected to hit blockbuster standing — gross sales of $1B or higher — by 2027.

Drugmakers on this listing embody AstraZeneca (AZN), AbbVie (NYSE:ABBV), Bristol-Myers Squibb (NYSE:BMY), Eli Lilly (LLY), Gilead Sciences (GILD), Johnson & Johnson (JNJ), and Pfizer (PFE).

The report gives a dose of confidence to the pharma and biotech industries provided that solely 37 new molecular entities in 2022, the bottom since 2016.

Although 2023 would not promise to be a stroll within the park, given patent cliffs and capital funding challenges, pharma and biotech “is on the cusp of unlocking revolutionary applied sciences that might vastly advance human well being,” Clarivate stated.

Here are a number of the therapies Clarivate estimates have blockbuster potential.

Approved by the US FDA earlier in January, Leqembi, from Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALY), is poised to develop into a key therapy for early to mid-stage Alzheimer’s. The monoclonal antibody deal with targets amyloid beta plaque within the mind to sluggish development of the illness.

Leqembi is nearly sure to develop into a blockbuster given one vital situation: CMS renders a constructive National Coverage Determination, one thing the company didn’t do for the companies’ different accepted Alzheimer’s therapy, Aduhelm (aducanumab). CMS is prone to make that call later this 12 months. Should Leqembi be granted full approval — it presently has accelerated approval — it’d help CMS in rendering a constructive determination.

Leqembi’s listing worth is $26.5K based mostly on twice month-to-month infusions. Goldman Sachs has projected the therapy might attain $15.7B in international peak gross sales in 2035.

Approved in September 2022, Bristol-Myers Squibb’s Sotyktu is one in all two remedies for plaque psoriasis to make the listing. The different is UCB’s (OTCPK:UCBJF)(OTCPK:UCBJY) Bimzelx (bimekizumab), a twin IL-17 A/F inhibitor.

Sotyktu, a tyrosine kinase 2 (TYK2) inhibitor, was accepted and not using a “black field warning,” which many analysts noticed as a big constructive. They additionally considered the approval as taking away market share from Amgen’s (AMGN) Otezla (opremilast).

Bristol (BMY) has beforehand acknowledged Sotyktu might see $4B in peak gross sales assuming indications in different inflammatory ailments.

With a number of section 3 trials ongoing, capivasertib, a selective ATP-competitive pan-AKT kinase inhibitor from AstraZeneca (AZN), might develop into a brand new therapy within the armamentarium for breast most cancers. In 2022, the corporate reported that including capivasertib to Fasdolex (fulvestrant) led to a 40% discount within the danger of illness development or demise in comparison with Fasdolex alone.

Revenues might attain $3.8B by 2038, in line with GlobalData.

GlaxoSmithKline’s (NYSE:GSK) daprodustat, a HIF prolyl-hydroxylase inhibitor for persistent kidney illness in sufferers on dialysis with anemia, has an FDA motion date of Feb. 1. In October 2022, an company advisory panel overwhelmingly voted in assist of the candidate.

The drug works by selling erythropoiesis, also called purple blood cell manufacturing.

Daprodustat has already been accepted in Japan. Jefferies has estimated peak gross sales of $1B.

AbbVie (ABBV) is growing this new reformulation of the usual of look after Parkinson’s, carbidopa/levodopa. The remedy is delivered by a subcutaneous pump.

Clarivate stated that foscarbidopa/foslevodopa gives higher efficacy than oral carbidopa/levodopa, has extra versatile dosing, and a extra handy pump than present and potential rivals.